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Triple-negative breast cancers (TNBCs), defined by lack of expression of estrogen receptor, progesterone receptor and HER2,
account for 12–17% of breast cancers and are clinically perceived as a discrete breast cancer subgroup. Nonetheless, TNBC has
been shown to constitute a vastly heterogeneous disease encompassing a wide spectrum of entities with marked genetic,
transcriptional, histological and clinical differences. Although most TNBCs are high-grade tumors, there are well-characterized
low-grade TNBCs that have an indolent clinical course, whose natural history, molecular features and optimal therapy vastly differ
from those of high-grade TNBCs. Secretory and adenoid cystic carcinomas are two histologic types of TNBCs underpinned by
specific fusion genes; these tumors have an indolent clinical behavior and lack all of the cardinal molecular features of high-grade
triple-negative disease. Recent studies of rare entities, including lesions once believed to constitute mere benign breast disease
(e.g., microglandular adenosis), have resulted in the identification of potential precursors of TNBC and suggested the existence of a
family of low-grade triple-negative lesions that, despite having low-grade morphology and indolent clinical behavior, have been
shown to harbor the complex genomic landscape of common forms of TNBC, and may progress to high-grade disease. In this
review, we describe the heterogeneity of TNBC and focus on the histologic and molecular features of low-grade forms of TNBC.
Germane to addressing the challenges posed by the so-called triple-negative disease is the realization that TNBC is merely a
descriptive term, and that low-grade types of TNBC may be driven by distinct sets of genetic alterations.
npj Breast Cancer (2016) 2, 16036; doi:10.1038/npjbcancer.2016.36; published online 16 November 2016
INTRODUCTION
Triple-negative (TN) breast cancers (TNBCs), defined by the lack of
expression of estrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor 2 (HER2), account
for 12–17% of breast cancers.1 TNBCs have been shown to have a
relatively aggressive clinical behavior, a high prevalence in women
of Hispanic and African descent, an earlier age of presentation2
and a significant association with BRCA1 germline mutations.1 As a
group, TNBCs display a high risk of metastasis and death within
5 years after diagnosis.3 Nonetheless, TNBC is vastly heteroge-
neous and best considered as an umbrella term, encompassing a
wide spectrum of entities with marked genetic, transcriptional,
histological, and clinical differences.4 Although most TNBCs are of
high grade and do display a relatively aggressive clinical behavior,
there are forms of low-grade TN disease, which have been shown
to have a more indolent behavior (Figure 1).5–7 In addition, recent
studies have brought forth the existence of lesions initially
thought to be mere benign breast conditions that likely constitute
precursors of TNBCs.8,9
Here, we review the heterogeneity of TNBC and focus on the
histologic and molecular features of low-grade forms of TNBC. The
realization that TNBC is merely a descriptive term, and that
low-grade types of TNBC may harbor distinct genetic alterations is
central to the successful classification of these lesions into
subtypes that are clinically meaningful and representative of the
biology of the disease, and to the tailoring of therapies for patients
with TNBC.
DEFINITION OF TNBC
The term TNBC was first used in 2005 (ref. 10) to refer to a subset
of breast cancer patients for whom chemotherapy was the only
treatment available, given that patients with TN disease lack ER,
PR, and HER2 and, therefore, are not eligible to receive hormonal
therapy or anti-HER2 agents. From a scientific and translational
research standpoint, the TN phenotype was also of interest, given
that it was initially perceived as a potential surrogate for basal-like
breast cancers, one of the ‘intrinsic gene’ subtypes of the disease
characterized by lack of ER and HER2 mRNA expression, but
expressing genes usually found in basal/ myoepithelial cells of the
normal breast.11 Currently, TNBCs should be defined as invasive
breast cancers lacking ER and PR expression and HER2 over-
expression/HER2 gene amplification according to the definitions
put forward in the American Society of Clinical Oncology/College
of American Pathologists guidelines for the assessment of ER, PR,
and HER2,12,13 as these definitions refer to a subset of breast
cancer patients who are not eligible for endocrine and anti-HER2
therapies.
GENETIC HETEROGENEITY OF TNBC
Given that the unifying feature of TNBCs is the lack of three
biomarkers, the genomic heterogeneity of these tumors should
not come as a surprise. As a group, TNBCs have been shown to be
characterized by high levels of genetic instability, with a median of
1.7 (range 0.16–5.23) mutations/Mb,14,15 and complex patterns of
copy number alterations (CNAs) and structural rearrangements.16
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Unlike other forms of breast cancer, where several genes have
been found to be mutated in 410% of cases, the only known
cancer genes targeted by somatic mutations in 10% or more of
TNBCs are TP53 and PIK3CA (Figure 2). Importantly, however,
TNBCs display a great variation in mutational content. Although
some TNBCs harbor a limited number of somatic mutations, others
display a high mutational burden affecting genes pertaining to
numerous signaling pathways.17 In a way akin to ER-positive
breast cancers, the most frequently mutated genes in TNBCs are
TP53 and PIK3CA, which are mutated in 82 and 10% of consecutive
TNBCs, respectively.18 In contrast to ER-positive carcinomas,
however, TP53 somatic mutations in TNBCs are enriched for
nonsense single-nucleotide variants and indels.17,18 Importantly,
however, somatic mutations affecting other known cancer driver
genes, including PTEN, RB1, NF1, BRCA1, BRCA2, ERBB3, ERBB4, ALK,
are found in small subsets of TNBCs (Figure 2).18
The heterogeneity in mutational content observed in TNBCs is
paralleled with an ample variation in their clonal composition,
with the number of clones/subclones identified in a single tumor
ranging from one to two per case, to multiple clones/subclones in
some cases, underscoring a great variation in clonal evolution.
TP53, PIK3CA, and PTEN mutations appear to be acquired early in
tumorigenesis, whereas mutations involving cell motility and
epithelial-to-mesenchymal transition genes display lower clonal
frequencies, suggesting that those represent later events in tumor
evolution.17 Importantly, in a substantial fraction of tumors,
founder somatic mutations such as TP53 and PIK3CA can be
subclonal,17 providing evidence to suggest that a large subset of
TNBCs are composed of mosaics of cancer cells at diagnosis.17
TNBCs, as a group, display complex patterns of CNAs, with
multiples gains and losses intercalated across all the chromosomes
and few focal high-level amplifications.19 Recurrent CNAs found in
TNBCs include gains of 1q, 8q, and 10p, and losses of 5q and 8p, as
well as PARK2 intragenic deletions, EGFR and FGFR2 amplifications,
and PTEN loss.17–21 Notably, TNBCs lack concurrent 1q gains and 16q
losses, changes typically found in ER-positive breast cancers.22,23
Functionally recurrent gene rearrangements have been
described in TNBC. A subset of TNBCs harbor gene fusions
involving Notch genes (NOTCH1 and NOTCH2) and microtubule-
associated serine-threonine kinase genes (MAST1 and MAST2),
which appear to be mutually exclusive.24 These findings might
open new therapeutic avenues, as preclinical studies have shown
that patient-derived xenograft models of Notch-altered tumors
and cell lines harboring Notch fusion genes have been reported to
be sensitive to Notch signaling inhibition.24,25 In addition, Banerji
et al.26 reported on a recurrent MAGI3–AKT3 fusion gene enriched
in TNBC, which was detected in 7% of TNBC cases (5/72) by
reverse transcription PCR (RT-PCR). A subsequent break-apart
Figure 1. The spectrum of histologic subtypes of TNBCs and a non-obligate precursor of TNBC. (a) High-grade invasive ductal carcinoma of no
special type, (b) low-grade adenoid cystic carcinoma, (c) low-grade acinic cell carcinoma, (d) microglandular adenosis, (e) low-grade
metaplastic adenosquamous carcinoma, (f) high-grade apocrine carcinoma, (g) high-grade metaplastic spindle cell carcinoma, (h) high-grade
metaplastic squamous cell carcinoma, and (i) high-grade carcinoma with medullary features. TNBC, triple-negative breast cancer.
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fluorescence in situ hybridization and RT-PCR study of 236 TNBCs
failed to detect the MAGI3–AKT3 fusion gene.27 Reanalysis of the
cases reported by Banerji et al.26 to harbor the MAGI3–AKT3 fusion
gene using a hybrid capture array confirmed the presence of this
fusion gene in a single TNBC, suggesting that the AKT3–MAGI3
fusion gene is either a private genetic event or that its prevalence
is substantially lower than that reported by Banerji et al.26
POST-NEOADJUVANT CHEMOTHERAPY OF TNBC
Although neoadjuvant systemic therapy does not improve the
overall survival of breast cancer patients compared with adjuvant
chemotherapy, the achievement of pathologic complete response
(pCR) following neoadjuvant chemotherapy is associated with an
improved prognosis. TNBCs display the highest rates of pCR
following neoadjuvant chemotherapy,1,28–30 with approximately
35–50% of TNBCs achieving pCR following anthracycline+taxane
neoadjuvant chemotherapy regimens.28,30 Importantly, the
patients with TNBC who achieve pCR have been shown to have
an excellent long-term clinical outcome, with very few distant
relapses; on the other hand, patients who have residual disease
after neoadjuvant chemotherapy have a poor prognosis.1,28–30
A subset of TNBCs has been suggested to harbor homologous
recombination DNA repair defects similar to those found in
tumors arising in BRCA1 and BRCA2 mutation carriers.31 Given that
tumors with homologous recombination DNA repair defects may
show greater sensitivity to agents that cause DNA double-strand
breaks and crosslinks,32,33 such as platinum salts and inhibitors of
the Poly(ADP) Ribose Polymerase (PARP), it has been posited that,
as a group, patients with TNBCs may benefit from platinum-based
chemotherapy. There is burgeoning evidence to demonstrate that
a subset of TNBC patients may benefit from the addition of
platinum-based chemotherapy to current chemotherapy regi-
mens. Randomized prospective clinical trials (CALGB 40603 and
GeparSixto)30,34 have demonstrated that the addition of carbo-
platin to doxorubicin and paclitaxel in patients with TNBC results
in significantly higher rates of pCR than the current anthracycline
+taxane-based chemotherapy (pCR rates 60% (54–66%) vs. 46%
(40–53%) in the CALGB 40603 trial34 and 53.2% (54.4–60.9%) vs.
36.9% (29.4–44.5%) in the GeparSixto trial30). Although the
concept of BRCAness is known for over a decade,31 biomarkers
to define which TNBC patients are likely to benefit from this
regimen have yet to be fully developed.35
Given that TNBC patients with residual disease after neoadju-
vant chemotherapy have a shorter overall survival than patients
with non-TN breast cancers,36 the identification of targetable
alterations in TN residual disease is of paramount importance.
Balko et al.37 have recently analyzed a series of 74 residual TNBCs
following neoadjuvant chemotherapy and showed that 490% of
cases had alterations in at least one clinically targetable pathway
(PTEN, JAK2, CDK6, CCND1, CCND2, CCND3 and IGF1R). In addition,
a higher frequency of potentially targetable alterations was
detected in post-treatment TNBCs compared with primary basal-
like breast cancers from TCGA. A frequent MYC and MCL1
co-amplification in residual TNBCs following neoadjuvant
chemotherapy was detected, with MCL1 gains in 83% of
MYC-amplified cases. Moreover, concurrent forced expression of
MYC and MCL1 in MCF10A cells enhanced cellular colony
formation, whereas their silencing increased cellular sensitivity to
doxorubicin.37
The same group has also identified in TNBCs following
neoadjuvant chemotherapy downregulation of DUSP4, a phos-
phatase that negatively regulates members of the MAP-kinase
pathways.38 Reduced expression of DUSP4 was found to be
associated with a worse outcome in TNBC patients,39 and when
detected in TNBCs after neoadjuvant therapy DUSP6 reduced
expression was associated with treatment-refractory high Ki67
scores and shorter recurrence-free survival.38 In addition, MEK
inhibition synergized with docetaxel in TNBC xenografts,38
suggesting that this therapeutic combination might potentially
benefit TNBC patients with residual disease after neoadjuvant
chemotherapy.
Taken together, neoadjuvant therapy of patients with TNBC has
revealed that a subset of these cancers is remarkably sensitive to
conventional cytotoxic agents and that this effect is increased by
the addition of platinum salts. Opportunities for translational
research in this area include the developments of biomarkers to
predict pCR in patients with TNBC, the analysis of post-
neoadjuvant chemotherapy residual disease, and whether this
residual disease differs from (micro)metastatic disease in these
patients.
TRANSCRIPTOMIC HETEROGENEITY OF TNBC
Albeit initially perceived as a synonym with basal-like breast
cancer at the transcriptomic level, several studies have demon-
strated that TNBCs display a great deal of heterogeneity and that
these two definitions are not synonymous.40 An additional
intrinsic subtype preferentially of TN phenotype was described
subsequently, namely claudin-low, which expresses low levels of
luminal differentiation markers, is enriched for the expression of
epithelial-to-mesenchymal transition, immune response and
cancer stem cell-related genes.41
The seminal studies carried out by Lehmann et al.42,43 further
demonstrated the transcriptional heterogeneity of TNBCs, reveal-
ing the existence of six subtypes of TN disease: basal-like 1, basal-
like 2, immunomodulatory, mesenchymal, mesenchymal stem-like
and luminal androgen receptor (LAR; Figure 3). Among the basal-
like subtypes, the basal-like 1 subset was found to be enriched in
cell division and DNA damage response pathways, whereas the
basal-like 2 group displayed an association with growth factor
signaling and myoepithelial marker expression. The immunomo-
dulatory subtype is characterized by immune cell processes and
immune signaling cascades. Although the mesenchymal stem-like
and mesenchymal subtypes share several transcriptomic simila-
rities and are enriched for genes implicated in cell motility and
epithelial-to-mesenchymal transition, the mesenchymal stem-like
subtype displays lower expression of genes associated with
cellular proliferation, and is enriched for genes related to
mesenchymal stem cells. The LAR subtype displays a luminal-like
gene expression pattern despite ER-negativity, most likely due to
Figure 2. Somatic mutations affecting cancer genes in TNBCs from
The Cancer Genome Atlas (TCGA). Bars indicate the frequency of
somatic mutations affecting the 50 cancer genes most frequently
mutated in TNBCs, based on a reanalysis of the 77 TNBCs from
TCGA.18 Cancer genes are defined as per the cancer gene lists
described by Kandoth et al.14 (127 significantly mutated genes), the
Cancer Gene Census,113 or Lawrence et al.114 (Cancer5000-S gene
set). TNBC, triple-negative breast cancer.
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androgen receptor activation. Comparative analyses of these six
subtypes with the intrinsic gene subtypes (Figure 3b) revealed
that basal-like 1, basal-like 2, immunomodulatory and mesench-
ymal TNBCs are preferentially of basal-like intrinsic subtype, that a
large proportion of mesenchymal stem-like TNBCs fit the intrinsic
normal-like or claudin-low43,44 subtypes, and that the LAR
subgroup corresponds in most part to the rare TNBCs classified
by PAM50 as luminal or HER2-enriched.42,43 It should be noted
that this six TNBC subtype classification may have therapeutic
implications, given that (i) xenografts of breast cancer cell lines
classified as of basal-like subtypes were found to be sensitive to
platinum salts, whereas mesenchymal and LAR subtype xenografts
were sensitive to PI3K/mTOR pathway inhibition and anti-
androgen therapy, respectively;42 and (ii) that approximately
50% of patients with basal-like 1 TNBCs were reported to evolve to
pCR following standard neoadjuvant chemotherapy, whereas the
pCR rates for other subgroups, such as LAR (10%) and basal-like 2
(0%), were found to be markedly lower.45
Curtis et al.23 proposed an alternative taxonomy for breast
cancer based on the integration of CNAs and gene expression
profiles, which defined 10 integrative clusters (IntClust 1–10).
IntClust 10 is composed mainly by poorly differentiated TNBCs,
with highly recurrent TP53 mutations and intermediate genomic
instability, and is characterized by poor prognosis in the first
5 years after diagnosis. On the other hand, approximately a fourth
of all TNBCs correspond to the IntClust 4 subtype, which has low
levels of genomic instability, absence of CNAs, marked
lymphocytic infiltrate and a better outcome,46 providing another
level of evidence to demonstrate the genomic heterogeneity
of TNBCs.
Figure 3. Comparative analysis of molecular subclassification systems applied to TNBCs. (a) Prevalence of each subtype according to PAM50,43
Lehmann et al.,43 and Burstein et al.47 (b) Comparison between the distinct classifications; Burstein et al. versus PAM50,47 Lehmann et al. versus
PAM50,43 and Burstein et al. versus Lehmann et al.47 BL1, basal-like 1; BL2, basal-like 2; BLIA, basal-like immune-activated; BLIS, basal-like
immunosuppressed; IM; immunomodulatory; LAR, luminal androgen receptor; LumA, luminal A; LumB, luminal B; M, mesenchymal; MES,
mesenchymal; MSL, mesenchymal stem-like; TNBC, triple-negative breast cancer; UNC, unclassified.
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More recently, Burstein et al.47 put forward yet another gene
expression classification, which categorizes TNBCs in luminal/
androgen receptor (LAR), mesenchymal (MES), basal-like/immune-
suppressed (BLIS), and basal-like/immune activated (BLIA) sub-
types (Figure 3), which have distinct clinical outcomes. The BLIS
subset displays the best outcome, whereas the BLIA subgroup
confers the poorest prognosis.47 Moreover, subtype-specific gene
amplifications were detected. LAR, MES, BLIS, BLIA subtypes
harbor amplifications of CCND1, EGFR, FGFR2, and CDK1, respec-
tively. Although ‘Burstein’s’ and ‘Lehmann’s’ LAR and mesenchy-
mal subtypes showed significant overlap, Burstein’s BLIS and BLIA
subtypes were a mixture of Lehmann’s groups47 (Figure 3b),
suggesting that not all TNBC gene expression subtypes are stable
and reproducibly identified, as previously demonstrated for the
intrinsic gene subtype classification.48
THE IMMUNE MILIEU AS A PROGNOSTIC AND PREDICTIVE
FACTOR FOR TNBC
Gene expression profiling has allowed significant progress in our
ability to assess prognosis and predict response to therapy in
breast cancer.49 First-generation prognostic signatures,50 which
rely markedly on proliferation-related genes, allow reliable
stratification of ER-positive breast cancer, however these have a
limited utility in TNBC, mainly due to the high proliferative nature
of most ER-negative cancers, and, therefore, the lack of
discriminatory power of first-generation prognostic signatures in
triple-negative disease. Activation of immune response genes was
shown, however, to be a good prognostic factor in ER-negative
cancers.51,52 Second-generation signatures based on immune
response-related genes have been developed;53,54 although these
signatures allow for the stratification of TNBC patients according
to overall and relapse-free survival, their clinical utility remains
negligible owing to the high number of events in this population,
even in patients with favorable signatures.49
Along the same lines, the relevance of the tumor-infiltrating
lymphocytes (TILs) as a prognostic and predictive biomarker in
TNBC is increasingly appreciated. In 2010, Denkert et al.55
described a quantitative assessment of TILs as a predictor of
response to neoadjuvant chemotherapy. Subsequent retrospec-
tive analyses of clinical trials have confirmed that the levels of TILs
are predictive of pCR and increased disease-free or overall
survival,56,57 and guidelines for evaluation of TILs in breast cancer
were provided by the International TIL Working Group.58 Although
the analytical validity and reproducibility of those guidelines have
been demonstrated in several studies,59,60 the clinical utility of TILs
assessment, in a way akin to the second-generation signatures,
remains limited given that TIL levels are prognostic in TNBC
patients treated with chemotherapy and robust evidence for
changing practice according to the levels of TILs has yet to be
provided.
A recent gene expression analysis of immune activating and
immunosuppressive factors in TNBC and HER2-positive carcino-
mas of the GeparSixto study unveiled three subgroups of tumors,
immune group A, B, and C with low, intermediate, and high
immune gene expression levels, respectively. Noticeably, tumors
belonging to the immune group C had a higher extent of TIL
infiltrate and better pCR rates than those of immune groups A and
B.61 Moreover, the extent of lymphocytic infiltrate in residual TNBC
following neoadjuvant chemotherapy has been associated with
metastasis-free and overall survival, highlighting the potential of
this biomarker in the post-neoadjuvant setting to identify patients
at risk of relapse.62
TNBCs: THE IMPORTANCE OF HISTOLOGIC SUBTYPING
The large majority of TNBCs are high-grade invasive carcinomas of
no special type displaying pushing invasive borders, central
necrosis, brisk lymphocytic infiltrates, marked nuclear pleomorphism,
and numerous mitoses.1,4 Nevertheless, there is a multitude of rare
histologic special types of breast cancer that are consistently of TN
phenotype (Figure 1).
Some high-grade special histologic types of breast cancer,
including carcinomas with apocrine features, carcinomas with
medullary features, and metaplastic breast carcinomas (MBCs)
almost invariably display a TN phenotype.63 Notably, among
TNBCs, carcinomas with apocrine features are the ones most likely
to express androgen receptor and display a molecular apocrine or
LAR gene expression profile.64 Thus, their identification may
suggest potential sensitivity to anti-androgen receptor agents and
may trigger androgen receptor testing, but does not carry definite
prognostic information as their outcome is uncertain and has
been reported to be comparable to that of conventional invasive
carcinomas of no special type.65 Likewise, contradictory data have
been published regarding the prognostic impact of androgen
receptor expression in TNBCs.66,67
Medullary carcinoma is a controversial histologic special type of
breast cancer, which has been reclassified as a histologic pattern
(i.e., carcinomas with medullary features) in the latest World
Health Organization classification.68 Well-circumscribed borders, a
syncytial growth pattern, and brisk lymphocytic infiltrate are the
hallmark features of the so-called medullary carcinoma; their
histologic identification, however, has been shown to lack in inter-
observer reproducibility. Despite worrisome cytological features
and high mitotic activity, carcinomas with medullary features are
historically perceived to have an excellent outcome.69 Given the
low inter-observer agreement rate for the identification of this
histologic subtype, a diagnosis of carcinoma with medullary
features does not carry any therapeutic implication and patients
with these cancers should be treated following the same protocols
for common forms of TNBC. In fact, one could argue that the good
prognosis historically reported to medullary carcinomas is merely
a reflection of the brisk lymphocytic infiltrate that these tumors
display, which has now been validated by level I evidence as a
prognostic marker for patients with TNBC treated with
chemotherapy.56,57
MBCs encompass a spectrum of tumors with squamous and/or
mesenchymal differentiation,70 are mostly high-grade lesions,
display worse outcome than conventional TNBCs,71 and show
significant inter- and intra-tumor heterogeneity.72,73 These tumors
are preferentially classified as of claudin-low or basal-like intrinsic
subtype,73–75 however, there is evidence that their histologic
subtype, as well as the subtype present in the sample subjected to
molecular analysis, have an impact on their genomic profile.73 The
spindle cell MBCs are preferentially of claudin-low intrinsic
subtype, whereas the squamous and chondroid MBCs are
classified more frequently as basal-like.73 At the genetic level,
MBCs are enriched for genetic alterations affecting Wnt and PI3K
pathways,75,76 in particular in the form of PIK3CA mutations. The
data on the repertoire of genetic alterations in MBCs is scarce,
however, our group has demonstrated that histologically distinct
morphological components within individual MBCs may display
distinct patterns of CNAs, despite being clonally related.72
Although as a group TNBCs display an aggressive clinical
behavior, a subset of these cancers are characterized by low
histologic grade and an indolent behavior. For example, even
among MBCs, low-grade variants exist, such as the low-grade
spindle and adenosquamous carcinomas, which display a less
aggressive clinical course.68 Among low-grade TN neoplasms, at
least two subsets can be distinguished: (i) carcinomas with salivary
gland-like morphology, which are underpinned by specific/
pathognomonic genetic alterations and display low-to-
intermediate levels of genetic instability; (ii) a subgroup of low-
grade lesions, including lesions once considered to be benign
hyperplastic proliferations (i.e., microglandular adenosis (MGA)),
atypical lesions (i.e., atypical microglandular adenosis (AMGA)) and
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invasive carcinomas (i.e., acinic cell carcinoma (ACC)), that, despite
their low-grade morphology and good outcome, recapitulate the
complex genomic landscape of usual TNBCs (Figures 4 and 5).
Salivary gland-like tumors of the breast
This group of TNBCs recapitulate neoplasms primary of the
salivary glands not only morphologically, but also genetically. In
contrast to conventional TNBCs, these tumors lack recurrent TP53
aberrations, display few copy number alterations and harbor
specific/pathognomonic genetic alterations. This group includes
the well-characterized adenoid cystic carcinoma (AdCC) and
secretory carcinoma, underpinned by MYB–NFIB and ETV6–NTRK3
fusion genes, respectively.77,78 Additional lesions rarely occurring
in the breast, yet comprehensively studied when arising in the
salivary glands, can tentatively be included in this subgroup, such
as the polymorphous low-grade adenocarcinoma and mucoepi-
dermoid carcinoma, which are characterized by PRKD1 hotspot
mutations79 and MAML2 rearrangements,80 respectively. Adeno-
myoepitheliomas of the breast, though heterogeneous, are
frequently of TN phenotype and can be morphologically identical
to epithelial–myoepithelial carcinomas of the salivary glands.
Recent data suggest that their phenotypic similarities may be
underpinned by a similar constellation of mutations (Reis-Filho
et al., manuscript under review).81
Adenoid cystic carcinoma. AdCCs, albeit originally described in
the salivary glands, can also arise in other anatomical sites,
including the lungs and breast. Breast AdCCs account for less than
0.1% of breast carcinomas, and typically show a good prognosis,
in contrast to the poor long-term outcomes in head and neck
AdCCs.82 AdCCs are composed of a dual population of luminal and
myoepithelial/basal cells, growing in cribriform, tubular and/or
solid patterns. The vast majority (495%) is TN82 and at the
transcriptomic level they pertain to the basal-like subtype.83 No
data are available in regards to AdCC and the TNBC gene
expression classification by Lehmann et al.42
Regardless of its anatomic location, the hallmark genetic
alteration of AdCC is a rearrangement of the MYB gene, most
frequently in the form of MYB–NFIB fusion gene, resulting in the
t(6;9)(q22–23;p23–24) translocation.77 The prevalence of such
Figure 4. Progression from low- to high-grade within the proposed low-grade triple-negative breast neoplasia family and salivary gland-like
tumors of the breast. (a) Representative low-power magnification of a high-grade invasive carcinoma of no special type (left) arising in
microglandular adenosis (right). (b) Representative high-power magnification of microglandular adenosis with (c) diffuse immunohisto-
chemical expression of lysozyme, a marker of serous acinar differentiation. (d) Representative high-power magnification of associated high-
grade invasive carcinoma of no special type, with (e) focal lysozyme expression by immunohistochemistry. (f) Representative low-power
magnification of a high-grade invasive carcinoma of no special type (left) arising in an adenoid cystic carcinoma (right). (g) Representative
high-power magnification of a high-grade invasive carcinoma of no special type with (h) high Ki67 proliferation rate. (i) Representative high-
power magnification of associated adenoid cystic carcinoma with (j) low Ki67 proliferation rate.
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alteration ranges from 23 to 100% in breast AdCCs. Notably, breast
AdCCs lacking the MYB–NFIB rearrangement have been shown to
be morphologically similar to those harboring this fusion gene.84
Distinct rearrangements affecting a second MYB family gene
(MYBL1) have been demonstrated in AdCCs of other sites,85 acting
in remarkably similar ways, and theoretically also detectable in
breast AdCCs.
In contrast to common forms of TNBCs, AdCCs display quiet
genomes lacking high-level amplifications or homozygous
deletions,84 as well as CNAs frequently present in usual TNBCs,
such as 8q gain and 5q loss. Breast AdCCs rather show recurrent
17q21-q25.1 gains and 12q12-q14.1 losses.19,84 Interestingly,
AdCCs occurring in the salivary gland also display 12q13
losses.86 Similar to AdCCs of the salivary glands, the mutation
rate of breast AdCCs is low.84 They lack TP53 and PIK3CA somatic
mutations and preferentially harbor mutations affecting genes
associated with chromatin remodeling, cell adhesion and signal-
ing cascades.84 Breast AdCCs have also been shown to display
recurrent mutations in TLN2, MYB, and BRAF84,87 and to harbor
mutations in cancer genes reported to be mutated in salivary
glands AdCCs,86 such as SF3B1, FBXW7, and FGFR2.
High-grade transformation has been described in breast and
salivary gland AdCCs7,88,89 (Figures 4f and g). Notably, high-grade
TNBCs arising in low-grade AdCCs7 or high-grade basaloid
AdCCs90 may also harbor the MYB–NFIB fusion gene. Few studies
suggested that in salivary glands p53 (ref. 89) or PTEN91
inactivation, or yet MYC amplification88 may have a role in this
phenomenon. Our group has recently reported on two breast
AdCCs with high-grade transformation; our findings confirmed
that progression occurred via the acquisition of additional genetic
events and/or clonal selection; however, none of the genetic
alterations reported in the progression of salivary gland AdCCs
were found in breast AdCCs.7 In a distinct study of a single breast
AdCC metastasizing to the kidney,92 PIK3CA and PTEN mutations
were found in both the primary and metastatic tumors, but, the
metastatic deposits showed increased PTEN promoter methylation
and lower PTEN gene expression levels. It seems therefore unlikely
that a single genetic event is responsible for the high-grade
transformation observed in human AdCCs.
Secretory carcinoma. Secretory carcinoma is a rare entity,
accounting for less than 0.15% of breast cancers.68 Although
initially described in children and named ‘juvenile carcinoma’, it
was later shown to occur at a median age of 53 years.93 This entity
has an excellent clinical outcome, with protracted survival even in
the presence of nodal involvement and metastatic disease.93
Morphologically it displays tubular, solid and/or microcystic
growth patterns with intra- and extra-cellular dense eosinophilic
secretions. Although the vast majority of cases are low-grade
TNBCs, cases of high-grade or with weak hormone receptor
expression have been reported.6
Over 90% of secretory carcinomas harbor the t(12;15)(p13;q25)
translocation resulting in the ETV6–NTRK3 fusion gene.78 Although
this translocation also underpins a variety of neoplasms of other
sites (i.e., infantile fibrosarcoma, cellular congenital mesoblastic
nephroma, acute myelogenous leukemia), in the context of breast
carcinomas it is pathognomonic of secretory carcinoma.94
Importantly, the ETV6–NTRK3 fusion protein can be inhibited by
crizotinib95 and other small molecule inhibitors, potentially
offering a therapeutic strategy for the rare cases of metastatic
and chemoresistant breast secretory carcinomas.6
The salivary gland counterpart of breast secretory carcinoma
was first recognized due to the discovery that ETV6–NTRK3
translocation underpins lesions morphologically similar to breast
secretory carcinomas but previously classified as unusual variants
of salivary gland ACCs.96,97 These lesions were then renamed
mammary analog secretory carcinoma.96 A later study found that
these tumors may harbor ETV6 rearrangements with an unknown
partner (ETV6-X),98 which theoretically may also occur in the breast
counterpart.
Figure 5. Hypothetical model of potential evolutionary paths of TNBCs. We propose that in addition to high-grade TNBCs, two subtypes of
low-grade TNBCs can be identified on the basis of their distinctive histology and molecular features: salivary gland-like tumors of the breast,
which are underpinned by specific/pathognomonic genetic alterations, and the proposed low-grade breast triple-negative neoplasia family,
whose tumors display genomic profiles similar to those of conventional high-grade TNBCs. Please note that both low-grade subgroups can
progress to high-grade TNBCs, however, the high-grade TNBCs arising in salivary gland-like tumors also differ from conventional TNBCs at the
genetic level and harbor the same genetic aberrations identified in their respective low-grade counterparts. TNBC, triple-negative breast
cancer.
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Secretory carcinomas have simple genomes with few CNAs.6,99
Recurrent 8q, 1q, 16pq, and 12p gains, along with 22q losses have
been identified.6,99,100 Del Castillo et al.6 have reported on a case
of a lethal high-grade secretory carcinoma with fluorescence
in situ hybridization-proven ETV6 rearrangement, which despite
harboring a simple genome, displayed more gains and losses of
entire chromosomes and chromosomal arms than lower-grade
tumors. Further studies of secretory carcinomas with high-grade
transformation are warranted to define their prognosis and
molecular underpinning.
Low-grade TN breast neoplasia family
It is currently perceived that breast cancer evolution can be
stratified into two main pathways according to ER pathway
activation.101 ER-positive breast neoplasms encompass a spectrum
of pre-invasive (columnar cell lesions, atypical ductal hyperplasia,
lobular neoplasia, and low-grade ductal carcinoma in situ) and
invasive lesions (invasive tubular, lobular, and low-grade ductal
carcinomas), and progression from low- to high-grade lesions may
take place.22 Owing to their frequent coexistence and similar
pattern of genetic alterations (e.g., PIK3CAmutations and deletions
of 16q and gains of 1q23,101), low-grade ER-positive non-obligate
precursors and invasive carcinomas have been grouped together
under the term ‘low-grade breast neoplasia family’.101
Akin to the low-grade ER-positive breast neoplasia family, a
subset of related low-grade neoplastic entities can also be
distinguished among the TN lesions of the breast. Indeed, MGA,
AMGA, and ACC show overlapping morphology and immunophe-
notype (lack of ER, PR, and HER2 and expression of S100 protein),
and are characterized by nearly indistinguishable genomic land-
scapes to those of common forms of TNBC.8,9,102–106 When not
associated with high-grade TNBCs, these lesions have an indolent
clinical behavior and limited metastatic potential despite the
worrisome genomic landscape, and should be managed accord-
ingly. Progression to high-grade TNBCs, however, is not
uncommon.102 Notably, in both ACC and MGA/AMGA, the
development of metaplastic TNBC has been reported by
independent investigators.9,105 We can therefore hypothesize
within the ER-negative branch of breast cancer evolution the
existence of a ‘low-grade TN breast neoplasia family’ comprising
MGA, AMGA, and ACC, which may give rise to bona fide high-
grade TNBCs (Figures 4a–e).106
Microglandular adenosis. MGA is histologically characterized by a
haphazard proliferation of small glands infiltrating adipose and
collagenous tissue, without eliciting a desmoplastic reaction.68
Although surrounded by a basement membrane, MGA acini lack a
myoepithelial cell layer, in a way akin to invasive carcinomas.
Although some have regarded MGA as a benign hyperplastic
lesion,103 it is currently recognized that MGA encompasses a
spectrum of lesions including pure MGA without atypia,
atypical MGA (AMGA), and MGA associated with invasive
carcinoma.8,9,102–106 Notably, MGA, AMGA, and associated high-
grade TNBCs display a similar phenotype, including the expression
of S100 protein, and pattern of genetic alterations.8,9,104–106 These
findings are consistent with the notion that MGA/AMGA are in fact
clonal neoplastic lesions and non-obligate precursors of TNBCs.
As a group, MGA/AMGA display complex copy number profiles
with recurrent 5q losses and 8q gains.9,104,105 Massively parallel
sequencing analysis has revealed that these lesions harbor highly
recurrent (~80%) TP53 mutations and a vast repertoire of mutated
genes at low frequency, including BRCA1, PI3K pathway genes
(PTEN, PIK3CA, and INPP4B) and genes encoding for receptor
tyrosine kinases (ERBB3, FGFR2).9 Significant heterogeneity, how-
ever, is observed. Current data favor that the majority of pure
MGAs differ from carcinoma-associated MGA/AMGA, given that
pure MGAs lack TP53 mutations and copy number alterations
affecting genomic regions commonly altered in TNBCs. It is
therefore possible that acquisition of TP53 mutations is a driver of
progression of MGAs and that the early genetic alterations
responsible for the development of these lesions have yet to be
unveiled.9
Acinic cell carcinoma. ACC grows in microglandular and nested
patterns and is defined by the presence of diffuse serous
differentiation featuring fine cytoplasmic zymogen-type granules,
reminiscent of the acinic cells in the salivary glands.107 Notably,
serous differentiation is also observed in MGA and MGA-
associated carcinomas.5,106 ACCs have a good prognosis, with
infrequent local and distal recurrences.68 The latter are usually
associated with the presence of a high-grade component.108 In
fact, in a way akin to MGA, progression to a high-grade TNBC of
distinct histologic type may not be a rare event. In our series of
eight ACCs, six were admixed with a high-grade non-acinic cell
component.5
Unlike other low-grade TNBCs that resemble their salivary gland
counterparts at the genomic level, ACCs arising in the breast and
in the salivary glands appear to be different entities, with distinct
histologic features and genomic alterations.107,109 At the mole-
cular level, breast ACCs harbor a complex pattern of CNAs, with
recurrent gains of 1q, 2q, and 8q and losses of 3p, 5q, 12q, 13q,
14q, 17p, and 17q.5 In addition, they display a high mutational
burden with TP53 and PIK3CA mutations found in 80 and 10% of
cases, respectively. This is in stark contrast to salivary gland ACCs
that lack mutations affecting these genes.5,109 In addition, somatic
mutations of other genes altered in common forms of TNBC, such
as MTOR, CTNNB1, BRCA1, ERBB3, INPP4B, and FGFR2, have also
been observed in breast ACCs.5
Akin to common forms of TNBC,110 an association between ACC
and BRCA1 inactivation has been documented. A breast ACC has
been reported in a BRCA1 mutation carrier; the tumor harbored a
BRCA1 loss of heterozygozity coupled with a TP53 somatic
mutation.111 We have reported on an ACC with somatic BRCA1
loss of heterozygozity and TP53 mutation, in the background of a
germline frameshift BRCA1mutation, and an additional case with a
BRCA1 somatic truncating mutation with loss of heterozygozity of
the BRCA1 wild-type allele and TP53 somatic mutation.5 Finally, we
have also observed a case of MGA-associated carcinoma with
similar somatic alterations affecting BRCA1 and TP53,9 as well as
MGA lesions in BRCA1 mutation carriers (Geyer & Reis-Filho,
unpublished data). Somatic abrogation of BRCA1 and TP53 in
conditional mouse models usually gives rise to high-grade breast
tumors; nonetheless, some mice may develop well-differentiated
tumors.112 Taken together, these findings support the contention
that the concurrent loss of function of BRCA1 and TP53 does not
necessarily result in the development of high-grade breast
cancers.
CONCLUSION
TNBC is an operational term that defines a wide spectrum of
entities with different biology and clinical behavior. Although
most TNBCs are high-grade tumors with a relatively poor
prognosis, a subset of low-grade TNBCs displays a favorable
outcome. Low-grade TNBCs can be further classified in at least two
subgroups. The first comprises the heterogeneous group of
salivary gland-like tumors of the breast, where each entity is
underpinned by specific genetic fusion genes or hotspot
mutations, and lack the genomic features of common forms of
TNBCs. The second group, the so-called low-grade TN breast
neoplasia family, encompasses MGA, AMGA, and ACC, which are
phenotypically similar and recapitulate the genetic alterations
found in conventional TNBCs. Progression from low- to high-grade
lesions may occur in both subgroups (Figures 4 and 5), though
likely at a higher rate within the second group. Notably,
The spectrum of triple-negative breast cancer
F Pareja et al
8
npj Breast Cancer (2016) 16036 Published in partnership with the Breast Cancer Research Foundation
high-grade TNBCs arising in salivary gland-like tumors are
genetically more similar to their low-grade counterparts than to
conventional TNBCs and the high-grade TNBCs in this context also
harbor the pathognomonic genetic alteration that characterizes
the low-grade lesion. Despite additional methods to stratify TNBCs
into clinically meaningful subtypes being on record,42,43 histologic
subtyping of these tumors is not a mere academic exercise, given
that the therapeutic approaches for the rare low-grade subtypes
of TNBC fundamentally differ from those of high-grade TNBCs.
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